|4Mar 12, 4:40 PM ET

Petrova Penka 4

4 · Trillium Therapeutics Inc. · Filed Mar 12, 2021

Insider Transaction Report

Form 4
Period: 2021-03-10
Petrova Penka
Chief Development Officer
Transactions
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2021-03-102,70886,668 total
    Exercise: $0.30Exp: 2029-11-07Common Shares (2,708 underlying)
  • Exercise/Conversion

    Common Shares

    2021-03-10$0.30/sh+2,708$8162,708 total
  • Exercise/Conversion

    Common Shares

    2021-03-10$3.35/sh+2,604$8,7305,312 total
  • Sale

    Common Shares

    2021-03-10$11.08/sh5,312$58,8570 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2021-03-102,60452,084 total
    Exercise: $3.35Exp: 2028-11-08Common Shares (2,604 underlying)
Footnotes (4)
  • [F1]This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
  • [F2]The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7925 USD.
  • [F3]The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7925 USD.
  • [F4]25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES